Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3099 Neoplasms 2443 Carcinoma, Non-Small-Cell Lung 1867 Prostatic Neoplasms 1619 Colorectal Neoplasms 1426 Lung Neoplasms 1295 Multiple Myeloma 929 Neoplasm Metastasis 920 Leukemia, Myeloid, Acute 874 Pancreatic Neoplasms 848 Ovarian Neoplasms 799 Melanoma 784 Carcinoma, Hepatocellular 737 Stomach Neoplasms 639 Brain Neoplasms 636 Recurrence 633 Squamous Cell Carcinoma of Head and Neck 632 Head and Neck Neoplasms 609 Glioblastoma 567 Lymphoma 540 Uterine Cervical Neoplasms 539 Triple Negative Breast Neoplasms 505 Precursor Cell Lymphoblastic Leukemia-Lymphoma 499 Carcinoma, Renal Cell 499 Hematologic Neoplasms 463 Urinary Bladder Neoplasms 459 Endometrial Neoplasms 459 Colonic Neoplasms 442 Lymphoma, Non-Hodgkin 436 Sarcoma 434

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ALK-positive Advanced NSCLC × 1 year × Clear all

NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed

103 enrolled 23 charts

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡